High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2

Leukemia

Volumn 10, Issue 11, 1996, Pages 1758-1764

  Uharek, L ^a   Zeis, M ^a   Glass, B ^a   Steinmann, J ^a   Dreger, P ^a   Gassmann, W ^a   Schmitz, N ^a   Muller Ruchholtz W ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Immunotherapy; Interleukin 12; Natural killer cell

Indexed keywords

CD18 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CELL ADHESION MOLECULE; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MEMBRANE ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CELL MOTILITY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOLYSIS; DRUG EFFECT; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 0029816779     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, Mueller-Ruchholtz W. Allogeneic NK-cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1994; 59: 1734-1736.
2. Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, Mueller-Ruchholtz W. Induction of graft-versus-leukemia activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts. Bone Marrow Transplant 1994; 14: 711-715.
3. Uharek L, Glass B, Gaska T, Zeis M, Gassmann W, Löffler H, Mueller-Ruchholtz W. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model. Bone Marrow Transplant 1993; 12: 57-60.
4. Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro Malaspinia H, O'Reilly RJ, Keever CA. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75: 2250-2262.
5. Weiss L, Weigensberg M, Morecki S, Bar S, Cobbold S, Waldmann H, Slavin S. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunol Immunother 1990; 31: 236-242.
6. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 1995; 23: 196-201.
7. Soiffer RJ, Robertson MJ, Murray C, Cochran K, Ritz J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 1993; 82: 2790-2796.
8. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964-971.
9. Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant JP, Sauvage C, Troussard X, Nedellec G, Pico J, Huguet F, Stoppa AM, Broustet A, Sotto JJ, Pris J, Maraninchi D, Reiffers J. Consolidation treatment of adult acute lymphoblastic leukemia - a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995; 86: 1619-1628.
10. Teichmann JV, Ludwig WD, Seibt Jung H, Thiel E. Induction of lymphokine-activated killer cell against human leukemia cells in vitro. Blut 1989; 59: 21-24.
11. Naume B, Espevik T. Immunoregulatory effects of cytokines on natural killer cells. (Review). Scand J Immunol 1994; 40: 128-134.
12. Podlaski FJ, Nanduri VB, Hulmes JD, Pan YC, Levin W, Danho WC, R, Gately MK, Stern AS. Molecular characterisation of interleukin 12. Arch Biochem Biophys 1992; 294: 230-237.
13. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste MC, Kobayashi M, Young D, Nickbarg E, Wolf F, Trincieri G. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387-1398.
14. Kobayashi M, Van Leeuwen BH, Elsbury S, Martinson ME, Young IG, Hapel AJ. Interleukin-3 is significantly more effective than other colony-stimulating factors in long-term maintenance of human bone marrow-derived colony-forming cells in vitro. Blood 1989; 73: 1836-1841.
15. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HAW, Young D, Clark SC, Trinchieri G. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-879.
16. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G. Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992; 148: 92-98.
17. + NK cells. J Immunol 1992; 148: 2429-2436.
18. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young DH, Ritz J. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992; 175: 779-788.
19. Perussia B, Chan SH, D'Andrea A, Tsuji K, Santoli D, Pospisil MY, D, Wolf SF, Trinchieri G. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol 1992; 149: 3495-3502.
20. Chehimi J, Starr SE, Frank I, Rengaraju M, Jackson SJ, Llanes CK, M, Perussia B, Young D, Nickbarg E, Wolf F, Trincieri G. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175: 789-796.
21. Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994; 83: 1323-1328.
22. Stern AS Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AGF, Stremlo DL, Truitt T, Chizzonile R. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990; 87: 6808-6812.
23. Bartsch HH, Pfizenmaier K, Hanusch A, Scheurich P, Ücer U, Nagel GA. Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-α correlates with the degree of receptor down-regulation. lnt J Cancer 1989; 43: 235-240.
24. Manetti R, Gerosa F, Giudizi MG, Biagiotti R, Parronchi P, Piccinni MP, Sampognaro S, Maggi E, Romagnani S, Trinchieri G. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994; 179: 1273-1283.
25. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263: 235-237.
26. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy MW, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. Journal of Experimental Medicine 1993; 178: 1223-1230.
27. DeCesare SL, Michelini-Norris B, Blanchard DK, Barton DP, Cavanagh DR, Fiorica JV, Hoffman MS, Djeu JY. Interleukin-12-mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system. Gynecol Oncol 1995; 57: 86-95.
28. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. (Review). Stem Cells 1994; 12: 154-168.
29. Jacobsen SE, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J Exp Med 1995; 181: 1357-1363.
30. Jackson JD, Yan Y, Brunda MJ, Kelsey LS, Talmadge JE. Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood 1995; 85: 2371-2376.
31. Bacon CM, McVicar DW, Ortaldo JR, Rees RC, O'Shea JJ, Johnston JA. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 1995; 181: 399-404.
32. Gately MK, Desai BB, Wolitzky AC, Quinn PM, Dwyer CM, Podlaski FJF, Sinigaglia F, Chizonnite R, Gubler U. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147: 874-882.
33. Desai BB, Quinn PM, Wolitzky AG, Mongini PK, Chizzonite R, Gately MK. IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol 1992; 148: 3125-3132.
34. Rabinowich H, Herberman RB, Whiteside TL. Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol 1993; 152: 481-498.
35. Timonen T, Patarroyo M, Gahmberg CG. CD11a-c/CD18 and CP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. J Immunol 1988; 141: 1041-1046.
36. Axberg I, Ramstedt U, Patarroyo M, Beatty P, Wigzell H. Inhibition of natural killer cell cytotoxicity by a monoclonal antibody directed against adhesion-mediating protein gp 90 (CD18). Scand J Immunol 1987; 26: 547-554.
37. Tahara H, Zeh H, Pappo I, Nastala C, Robbins PD, Lotze MT. Suppressed growth of murine melanoma in vivo with local secretion of interleukin-12 delivered by transfected fibroblasts (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1993; 34: A2761.
38. Maranichi D, Blaise D, Viens P, Brandely M, Olive D, Lopez MS, D, Marit G, Stoppa AM, Reiffers J. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991; 78: 2182-2187.
39. Scott I, Bunce M, Lowdell M, O'Shea J, Tiercy J-M, Gavira N, Prentice C, Goldman J, Madrigal A. The role of HLA-C mismatching in T cell and natural killer alloreactivity in unrelated donor bone marrow transplant. Blood 1995; 86: 292a.
40. Raulet DH, Held W. Natural killer cell receptors: the offs and ons of NK cell recognition. Cell 1995; 82: 697-700.
41. Ploemacher RE, van Soest PL, Voorwinden H, Boudewijn A. Interleukin-12 synergizes with interleukin-3 and steel factor to enhance recovery of murine hemopoietic stem cells in liquid culture. Leukemia 1993; 7: 1381-1388.
42. Dybedal I, Larsen S, Jacobsen SE. IL-12 directly enhances in vitro murine erythropoiesis in combination with IL-4 and stem cell factor. J Immunol 1995; 154: 4950-4955.